MDMA Therapy 2026 Update: Where Things Stand After the FDA Rejection
The FDA rejected Lykos Therapeutics’ application for MDMA-assisted therapy for PTSD in August 2024, and as of mid-2026 that decision stands. MDMA remains a Schedule I...
Psychedelic Therapy FAQ: Honest Answers for the Educated Seeker
This psychedelic therapy FAQ compiles the most common and most important questions from people seriously considering psilocybin or other psychedelic-assisted approaches. The answers here are grounded...
The JOM11 Framework: Concierge Psychedelic Therapy for Executives
The JOM11 psychedelic executive program is JourneyOM’s structured, concierge-level pathway for senior leaders who want to address burnout, cognitive rigidity, or performance plateaus through professionally supported...
Psilocybin Eating Disorder Treatment: Early Evidence and Cautions
Psilocybin eating disorder treatment is an emerging area of clinical research, with early trials in anorexia nervosa showing that the compound is well-tolerated and may help...
Psilocybin and the Aging Brain: What the Research Shows So Far
Research into psilocybin aging effects is accelerating, with preclinical studies pointing to neuroplasticity promotion, reduced neuroinflammation, and improvements in longevity biomarkers. The findings are genuinely interesting,...
How to Talk to Your Doctor About Psychedelic Therapy
Talking to your doctor about psychedelic therapy is one of the most common points where people get stuck. This guide walks you through how to frame...
Psilocybin OCD Treatment: What the Early Research Shows
Psilocybin OCD treatment is a small but growing area of clinical research, with early data suggesting meaningful symptom reductions for people who have not responded to...
Psychedelic Therapy in Pennsylvania: Philadelphia, Pittsburgh & Legal Access
Psychedelic therapy in Pennsylvania is at an early but real stage of development. Ketamine is the only legally available psychedelic-assisted treatment within the state right now,...
Psilocybin for End-of-Life Anxiety: What the Research Shows
Research into psilocybin for end-of-life anxiety has produced some of the most compelling clinical data in psychedelic science. Landmark trials at Johns Hopkins and NYU found...
Psychedelic Therapy Contraindications: Who Should Pause First
Psychedelic therapy contraindications include a personal history of psychosis or mania, current lithium use, certain cardiac conditions, and active suicidal ideation with intent. Some of these...
Ready to take the next step?
Start with a complimentary conversation, or take the two-minute self-evaluation to see if this is your moment.